drugset / Trial / NCT01486966

Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes

NCT01486966

Phase 4 Terminated 58 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin detemir plus insulin aspart and NPH insulin plus human soluble insulin both in a basal bolus regimen with or without metformin in Chinese patients with type 2 diabetes. The trial adopts a group sequential design, where the analysis of the primary efficacy endpoint will be performed at the interim analysis, in addition to the final formal analysis. The decision to continue or stop the trial will be based on the result of the interim analysis.

Timeline

Start
2011-11
Primary completion
2012-06
Completion
2012-06

Publications

  • Results Guo X, Li Q, Shi Y, Bu R, Liu J, Qu S, Gao Y. Efficacy and safety of insulin detemir plus insulin aspart versus NPH insulin plus human soluble insulin with or without metformin in Chinese type 2 diabetes. Chinese J Diabetes 2014; 22 (1)

Drugs

EvaluationDrugModalityDoseRoute
Comparator human soluble insulin Protein / enzyme biologic Subcutaneous
Comparator insulin NPH Protein / enzyme biologic Subcutaneous
Subject insulin aspart Protein / enzyme biologic Subcutaneous
Subject insulin detemir Protein / enzyme biologic Subcutaneous
Background Metformin Small molecule